{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:23:34Z","timestamp":1791843814894,"version":"4.3.4"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Advanced endometrial cancer (EC) poses significant therapeutic challenges due to molecular heterogeneity and immune evasion. Immune checkpoint inhibitors (ICIs) show promise, particularly in mismatch repair-deficient (MMRd) and POLE-mutated subtypes, but resistance remains a barrier. This review synthesizes recent advances in biomarker-driven immunotherapy for EC, focusing on predictive biomarkers (e.g., LRP2, FANCE, MSH2, miRNA signatures), combination strategies (ICIs with anti-angiogenics or PARP inhibitors), and challenges in clinical translation. We highlight the impact of tumor microenvironment components, emerging technologies like machine learning, and future directions for personalized immunotherapy. Standardizing biomarker testing and optimizing trial designs will be critical to overcome resistance and improve outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1684549","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:29:33Z","timestamp":1760678973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications"],"prefix":"10.3389","volume":"16","author":[{"given":"Lianfang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00437","article-title":"Disease detection with molecular biomarkers: from chemistry of body fluids to nature-inspired chemical sensors","volume":"119","author":"Broza","year":"2019","journal-title":"Chem Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005243","article-title":"Evaluation of efficacy and adverse events after second immunotherapy exposure in endometrial and cervical carcinoma","volume":"142","author":"Morton","year":"2023","journal-title":"Obstet Gynecol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i6.2380","article-title":"Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma","volume":"16","author":"Wang","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15111344","article-title":"Screening blood and vitreous for biomarkers associated with proliferative diabetic retinopathy","volume":"15","author":"Richard","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2020.11.3.4","article-title":"Biomarker BINGO","volume":"11","author":"Held","year":"2020","journal-title":"J advanced practitioner Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnad062","article-title":"Predicting ketamine infusion therapy efficacy","volume":"24","author":"Andrassy","year":"2023","journal-title":"Pain Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005916","article-title":"Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier","volume":"34","author":"Jamieson","year":"2024","journal-title":"Int J gynecological cancer: Off J Int Gynecological Cancer Society"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S445055","article-title":"The clinical and pathological characteristics of POLE-mutated endometrial cancer: A comprehensive review","volume":"16","author":"Yao","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061478","article-title":"The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions","volume":"13","author":"Alexa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s44276-025-00145-2","article-title":"Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification","volume":"3","author":"Yoshimura","year":"2025","journal-title":"BJC Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.70206","article-title":"Integration of sentinel node mapping and molecular classification in endometrial cancer staging","volume":"171","author":"Bogani","year":"2025","journal-title":"Int J gynaecology obstetrics: Off Organ Int Fed Gynaecology Obstetrics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00432-024-05901-4","article-title":"Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach","volume":"150","author":"Mustea","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0177-x","article-title":"Clinical actionability of molecular targets in endometrial cancer","volume":"19","author":"Urick","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2025.12445","article-title":"Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia","author":"Wang","year":"2025","journal-title":"Biomolecules biomedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/path.6429","article-title":"Activated immune infiltrates expand opportunities for targeted therapy in p53-abnormal endometrial carcinoma","volume":"266","author":"Martin","year":"2025","journal-title":"J Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2020.12.010","article-title":"The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment","volume":"6","author":"Yang","year":"2021","journal-title":"Bioact Mater"},{"key":"B18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.modpat.2024.100624","article-title":"Spatial cancer-immune phenotypes predict shorter recurrence-free survival in the no specific molecular profile molecular subtype of endometrial carcinoma","volume":"38","author":"de Biase","year":"2025","journal-title":"Mod Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/pin.70030","article-title":"Increased expression of AXL and c-MET in high-grade clear cell renal cell carcinoma and its association with VEGFR-TKI treatment and PD-L1 expression","volume":"75","author":"Mikami","year":"2025","journal-title":"Pathol Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"106872","DOI":"10.1016\/j.compbiomed.2023.106872","article-title":"Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma","volume":"158","author":"Guo","year":"2023","journal-title":"Comput Biol Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"110021","DOI":"10.1016\/j.compbiomed.2025.110021","article-title":"A multi-omics analysis of effector and resting treg cells in pan-cancer","volume":"189","author":"Chalepaki","year":"2025","journal-title":"Comput Biol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e18","article-title":"Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer","volume":"34","author":"Hong","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0251-7","article-title":"TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers","volume":"32","author":"Moore","year":"2019","journal-title":"Mod Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03481-0","article-title":"Combination immunotherapy strategies for glioblastoma","volume":"151","author":"Chan","year":"2021","journal-title":"J Neurooncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2024.2367472","article-title":"Immunotherapy in MMR-d\/MSI-H recurrent\/metastatic endometrial cancer","volume":"24","author":"Pacholczak-Madej","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.862527","article-title":"Identification of a tumor immunological phenotype-related gene signature for predicting prognosis, immunotherapy efficacy, and drug candidates in hepatocellular carcinoma","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132460","article-title":"The role of immunotherapy in the management of esophageal cancer in patients treated with neoadjuvant chemoradiation: an analysis of the national cancer database","volume":"16","author":"Tasoudis","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12964-024-01792-7","article-title":"Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications","volume":"22","author":"Wang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103851","DOI":"10.1016\/j.critrevonc.2022.103851","article-title":"Advanced and recurrent endometrial cancer: State of the art and future perspectives","volume":"180","author":"Tronconi","year":"2022","journal-title":"Crit Rev oncology\/hematology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ygyno.2024.10.026","article-title":"KRAS mutations in endometrial cancers: Possible prognostic and treatment implications","volume":"191","author":"Kilowski","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GCO.0000000000000603","article-title":"Optimizing immunotherapy for gynecologic cancers","volume":"32","author":"Rubinstein","year":"2020","journal-title":"Curr Opin obstetrics gynecology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/BTT.S369783","article-title":"Novel molecular targets in endometrial cancer: mechanisms and perspectives for therapy","volume":"18","author":"Soberanis Pina","year":"2024","journal-title":"Biologics: Targets Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953115","article-title":"Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer","volume":"13","author":"Passarelli","year":"2022","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer","volume":"8","author":"Konstantinopoulos","year":"2022","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.04.029","article-title":"Uterine serous carcinoma","volume":"162","author":"Bogani","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-1664","article-title":"Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis","volume":"14","author":"Ge","year":"2022","journal-title":"J Thorac Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"102873","DOI":"10.4251\/wjgo.v17.i3.102873","article-title":"Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis","volume":"17","author":"Ni","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03455-y","article-title":"Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations","volume":"26","author":"Wang","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"9959946","DOI":"10.1155\/2021\/9959946","article-title":"Efficacy and safety of regorafenib combined with toripalimab in the third-line and beyond treatment of advanced colorectal cancer","volume":"2021","author":"Yu","year":"2021","journal-title":"J Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12890-025-03635-8","article-title":"Efficacy and safety of anlotinib monotherapy or combination therapy in the treatment of patients with advanced non-small cell lung cancer: a retrospective real-world study conducted in East China","volume":"25","author":"Wei","year":"2025","journal-title":"BMC Pulm Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-024-00866-z","article-title":"The use of biologic agents for the treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors: A review of reported cases","volume":"25","author":"Pach","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2162660","article-title":"Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Bioengineered"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1100285","article-title":"Characterization of cellular senescence patterns predicts the prognosis and therapeutic response of hepatocellular carcinoma","volume":"9","author":"Tang","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa029","article-title":"The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction","volume":"22","author":"Himes","year":"2020","journal-title":"Neuro Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304073","article-title":"Immunosuppression in stem cell clinical trials of neural and retinal cell types: A systematic review","volume":"19","author":"Gowrishankar","year":"2024","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618202","article-title":"The immunobiogram, a novel in vitro assay to evaluate treatment resistance in patients receiving immunosuppressive therapy","volume":"11","author":"Portoles","year":"2020","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.nucmedbio.2021.05.001","article-title":"Combination radionuclide therapy: A new paradigm","author":"Suman","year":"2021","journal-title":"Nucl Med Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4459","article-title":"Tumor immune microenvironment during epithelial-mesenchymal transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41419-021-04487-w","article-title":"The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype","volume":"13","author":"Sun","year":"2022","journal-title":"Cell Death Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02568-2","article-title":"Immunotherapy for endometrial cancer","volume":"30","author":"Wada","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S403778","article-title":"Metabolic reprogramming and its regulatory mechanism in sepsis-mediated inflammation","volume":"16","author":"Liu","year":"2023","journal-title":"J Inflammation Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.ccell.2023.07.007","article-title":"Proteogenomic insights suggest druggable pathways in endometrial carcinoma","volume":"41","author":"Dou","year":"2023","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7150\/thno.82920","article-title":"The role of lipid metabolic reprogramming in tumor microenvironment","volume":"13","author":"Yang","year":"2023","journal-title":"Theranostics"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1325360","article-title":"Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization","volume":"14","author":"Katopodi","year":"2023","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.07.010","article-title":"Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy","volume":"166","author":"Barrington","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i11.4518","article-title":"From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies","volume":"16","author":"Kong","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12885-025-13719-7","article-title":"Different NGS identification methods of somatic mutation sites in solid tumors impact TMB results","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179659","article-title":"Predictive biomarkers and resistance mechanisms of checkpoint inhibitors in Malignant solid tumors","volume":"25","author":"Pavelescu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/bios15020074","article-title":"Dual biomarker strategies for liquid biopsy: integrating circulating tumor cells and circulating tumor DNA for enhanced tumor monitoring","volume":"15","author":"Moon","year":"2025","journal-title":"Biosensors"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2021.10.043","article-title":"The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer","volume":"171","author":"Tran","year":"2022","journal-title":"Surgery"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001581","article-title":"BRG1, INI1, and ARID1B deficiency in endometrial carcinoma: A clinicopathologic and immunohistochemical analysis of a large series from a single institution","volume":"44","author":"Kihara","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.47162\/RJME.65.2.04","article-title":"Prognostic implications of immunohistochemistry in patients with endometrial cancer","volume":"65","author":"Anca-Stanciu","year":"2024","journal-title":"Romanian J morphology embryology = Rev roumaine morphologie embryologie"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.09.009","article-title":"Differential clinicopathologic features in microsatellite-unstable gastric cancers with and without MLH1 methylation","volume":"44","author":"Kim","year":"2013","journal-title":"Hum Pathol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13481","article-title":"Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening","volume":"25","author":"Urakami","year":"2018","journal-title":"Int J urology: Off J Japanese Urological Assoc"},{"key":"B73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/PAI.0000000000000389","article-title":"Small bowel adenocarcinoma frequently exhibits lynch syndrome-associated mismatch repair protein deficiency but does not harbor sporadic MLH1 deficiency","volume":"25","author":"Xia","year":"2017","journal-title":"Appl immunohistochemistry Mol morphology: AIMM"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000377","article-title":"Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers","volume":"25","author":"Kobayashi","year":"2015","journal-title":"Int J gynecological cancer: Off J Int Gynecological Cancer Society"},{"key":"B75","doi-asserted-by":"publisher","first-page":"153288","DOI":"10.1016\/j.prp.2020.153288","article-title":"Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer","volume":"217","author":"Lee","year":"2021","journal-title":"Pathology Res practice"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001432","article-title":"Mismatch repair deficiency in ovarian carcinoma: frequency, causes, and consequences","volume":"44","author":"Leskela","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/DCR.0000000000003527","article-title":"Clinicopathological characteristics and outcomes of colorectal cancer with heterogenous staining of mismatch repair protein","volume":"68","author":"Zhang","year":"2025","journal-title":"Dis colon rectum"},{"key":"B78","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12672-022-00528-8","article-title":"Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort","volume":"13","author":"Li","year":"2022","journal-title":"Discover Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s12672-025-02568-2","article-title":"Deciphering the interaction between the expression of LRP2 served as a mitochondrial metabolism-related gene and prognosis in colon cancer integrating multi-omics analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Discover Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa088","article-title":"Characteristics of genomic alterations in Chinese cholangiocarcinoma patients","volume":"50","author":"Jiang","year":"2020","journal-title":"Japanese J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddaa200","article-title":"LRP2 controls sonic hedgehog-dependent differentiation of cardiac progenitor cells during outflow tract formation","volume":"29","author":"Christ","year":"2020","journal-title":"Hum Mol Genet"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"100904","DOI":"10.1016\/j.blre.2021.100904","article-title":"A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis","volume":"52","author":"Gueiderikh","year":"2022","journal-title":"Blood Rev"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-023-36933-y","article-title":"Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress","volume":"14","author":"Tomaszowski","year":"2023","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.7150\/jca.86348","article-title":"Reduced FANCE confers genomic instability and Malignant behavior by regulating cell cycle progression in endometrial cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"J Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41698-018-0060-3","article-title":"Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response","volume":"2","author":"Vargas","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-021-00301-z","article-title":"Immunotherapy in endometrial cancer: rationale, practice and perspectives","volume":"9","author":"Cao","year":"2021","journal-title":"biomark Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1523518","article-title":"Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment","volume":"15","author":"Tashireva","year":"2024","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf089","article-title":"A working group report from the 2024 NCI\/GCSC endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era","volume":"117","author":"Cosgrove","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20203398","article-title":"An miRNA signature associated with tumor mutation burden in endometrial cancer","volume":"40","author":"Zhou","year":"2020","journal-title":"Biosci Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210208111821","article-title":"Advancements within modern machine learning methodology: impacts and prospects in biomarker discovery","volume":"28","author":"Ledesma","year":"2021","journal-title":"Curr medicinal Chem"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.07.005","article-title":"Hallmark guided identification and characterization of a novel immune-relevant signature for prognostication of recurrence in stage I-III lung adenocarcinoma","volume":"10","author":"Zhang","year":"2023","journal-title":"Genes Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12885-024-13418-9","article-title":"Identification and validation of glucose metabolism-related gene signature in endometrial cancer","volume":"25","author":"Jiang","year":"2025","journal-title":"BMC Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40364-022-00378-0","article-title":"The role of biomarkers in personalized immunotherapy","volume":"10","author":"Sankar","year":"2022","journal-title":"biomark Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-221261","article-title":"Neuropsychiatric symptoms and commonly used biomarkers of alzheimer's disease: A literature review from a machine learning perspective","volume":"92","author":"Shah","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01478-4","article-title":"Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review","volume":"42","author":"Na","year":"2024","journal-title":"Invest New Drugs"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1208132","article-title":"Integrative analysis of circadian clock with prognostic and immunological biomarker identification in ovarian cancer","volume":"10","author":"Zhao","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14603","article-title":"The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study","volume":"13","author":"Feng","year":"2022","journal-title":"Thorac cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.21-606","article-title":"Combinational elastography","volume":"63","author":"Sakamoto","year":"2022","journal-title":"Int Heart J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy174","article-title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","volume":"29","author":"Mirza","year":"2018","journal-title":"Ann Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12419","article-title":"Extracellular vesicles as a promising source of lipid biomarkers for breast cancer detection in blood plasma","volume":"13","author":"Dorado","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202957","article-title":"Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma","volume":"13","author":"Zhang","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.958161","article-title":"Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41576-022-00540-2","article-title":"Biomarker benchmarking","volume":"23","author":"Koch","year":"2022","journal-title":"Nat Rev Genet"},{"key":"B110","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","article-title":"Synergistic efficacy of simultaneous anti-TGF-beta\/VEGF bispecific antibody and PD-1 blockade in cancer therapy","volume":"16","author":"Niu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300121","article-title":"Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-015-0959-0","article-title":"Communication and US-somali immigrant human papillomavirus (HPV) vaccine decision-making","volume":"32","author":"Dailey","year":"2017","journal-title":"J Cancer education: Off J Am Assoc Cancer Education"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006944","article-title":"Id-neoantigen vaccine induces therapeutic CD8(+) T cells against multiple myeloma: H chain-loss escapees cause FLC MM","volume":"11","author":"Westhrin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000004359","article-title":"Neurotoxins and combination therapies","volume":"50","author":"Gawey","year":"2024","journal-title":"Dermatologic surgery: Off Publ Am Soc Dermatologic Surg [et al]"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111726","article-title":"Cell and cell free therapies in osteoarthritis","volume":"9","author":"Pelaez","year":"2021","journal-title":"Biomedicines"},{"key":"B116","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41746-022-00583-z","article-title":"Digital biomarkers: Convergence of digital health technologies and biomarkers","volume":"5","author":"Vasudevan","year":"2022","journal-title":"NPJ Digit Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03874-5","article-title":"CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches","volume":"27","author":"Kwantwi","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-024-09483-8","article-title":"The immunosuppressive landscape in tumor microenvironment","volume":"72","author":"Liu","year":"2024","journal-title":"Immunol Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202102271","article-title":"Calcium phosphate-reinforced metal-organic frameworks regulate adenosine-mediated immunosuppression","volume":"33","author":"Liang","year":"2021","journal-title":"Adv Mater"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15598","article-title":"CXC chemokine ligand-10 promotes the accumulation of monocyte-like myeloid-derived suppressor cells by activating p38 MAPK signaling under tumor conditions","volume":"114","author":"Sun","year":"2023","journal-title":"Cancer Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202305708","article-title":"Recent advances in reprogramming strategy of tumor microenvironment for rejuvenating photosensitizers-mediated photodynamic therapy","volume":"20","author":"Yu","year":"2024","journal-title":"Small"},{"key":"B122","doi-asserted-by":"publisher","first-page":"119826","DOI":"10.1016\/j.lfs.2021.119826","article-title":"Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints","volume":"282","author":"Baghbani","year":"2021","journal-title":"Life Sci"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030783","article-title":"Glioma stem cells upregulate CD39 expression to escape immune response through SOX2 modulation","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e4976","DOI":"10.1002\/bmc.4976","article-title":"Metabolomics analysis of multidrug resistance in colorectal cancer cell and multidrug resistance reversal effect of verapamil","volume":"35","author":"Wang","year":"2021","journal-title":"Biomed chromatography: BMC"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00028","article-title":"Novel approaches, drug candidates, and targets in pain drug discovery","volume":"64","author":"Obeng","year":"2021","journal-title":"J Med Chem"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-024-00999-7","article-title":"Inhibition of EREG\/ErbB\/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFbeta and Hedgehog signal pathway","volume":"47","author":"Xiu","year":"2024","journal-title":"Cell Oncol (Dordr)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.7555\/JBR.38.20240045","article-title":"Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer","volume":"39","author":"Lv","year":"2024","journal-title":"J Biomed Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"114658","DOI":"10.1016\/j.ejogrb.2025.114658","article-title":"Integrating locoregional therapy with ongoing immunotherapy after oligoprogression in recurrent\/metastatic cervical cancer","volume":"314","author":"Gorniak","year":"2025","journal-title":"Eur J obstetrics gynecology Reprod Biol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/s41467-021-22226-9","article-title":"Reversed evolution of grazer resistance to cyanobacteria","volume":"12","author":"Isanta-Navarro","year":"2021","journal-title":"Nat Commun"},{"key":"B130","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41541-024-00858-4","article-title":"Reverse development of vaccines against antimicrobial-resistant pathogens","volume":"9","author":"Bagnoli","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B131","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41584-024-01173-x","article-title":"Combination therapy for Behcet uveitis","volume":"20","author":"Webster","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13543784.2025.2463091","article-title":"Tumor immunology and immunotherapy for endometrial cancer","volume":"34","author":"Murakami","year":"2025","journal-title":"Expert Opin investigational Drugs"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002256","article-title":"p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification","volume":"31","author":"Jamieson","year":"2021","journal-title":"Int J gynecological cancer: Off J Int Gynecological Cancer Society"},{"key":"B134","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.fmre.2022.07.011","article-title":"Molecular biomarkers, network biomarkers, and dynamic network biomarkers for diagnosis and prediction of rare diseases","volume":"2","author":"Tang","year":"2022","journal-title":"Fundam Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008572","article-title":"Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer","volume":"16","author":"Fang","year":"2020","journal-title":"PloS Genet"},{"key":"B136","doi-asserted-by":"publisher","first-page":"107255","DOI":"10.1016\/j.lungcan.2023.107255","article-title":"Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study","volume":"181","author":"Tian","year":"2023","journal-title":"Lung Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.05.011","article-title":"Combination strategies and targeted radionuclide therapies","volume":"54","author":"Jewell","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15486","article-title":"High prevalence of \"non-pathogenic\" POLE mutation with poor prognosis in a cohort of endometrial cancer from South India","volume":"166","author":"Kuriakose","year":"2024","journal-title":"Int J gynaecology obstetrics: Off Organ Int Fed Gynaecology Obstetrics"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15012","article-title":"Integrating POLE\/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Thorac cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac017","article-title":"Non-exonuclease domain POLE mutations associated with immunotherapy benefit","volume":"27","author":"Dong","year":"2022","journal-title":"Oncologist"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246507","article-title":"Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice","volume":"16","author":"Ziemba","year":"2021","journal-title":"PloS One"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2022-0182-OA","article-title":"B7-H4 further stratifies patients with endometrial cancer exhibiting a nonspecific molecular profile","volume":"147","author":"Zong","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-025-00803-1","article-title":"Molecular characterization of mixed-histology endometrial carcinoma provides prognostic and therapeutic value over morphologic findings","volume":"9","author":"Haight","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010541","article-title":"Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer","volume":"13","author":"Roudko","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252697","article-title":"Analyzing biomarker discovery: Estimating the reproducibility of biomarker sets","volume":"17","author":"Forouzandeh","year":"2022","journal-title":"PloS One"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2023.2263874","article-title":"Neurodegenerative biomarkers outperform neuroinflammatory biomarkers in amyotrophic lateral sclerosis","volume":"25","author":"Klappe","year":"2024","journal-title":"Amyotrophic lateral sclerosis frontotemporal degeneration"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac709","article-title":"The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling study","volume":"62","author":"Wientjes","year":"2023","journal-title":"Rheumatology"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/jog.15730","article-title":"Mini-review: Immunology in ovarian cancer","volume":"49","author":"Taki","year":"2023","journal-title":"J obstetrics gynaecology Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.06.008","article-title":"Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy","volume":"48","author":"Gargiulo","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B152","doi-asserted-by":"publisher","first-page":"599","DOI":"10.12892\/ejgo3200.2016","article-title":"The role of microRNAs in endometrial cancer and influence on future therapy: focusing on miRNA-21","volume":"37","author":"Rak","year":"2016","journal-title":"Eur J gynaecological Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.17772\/gp\/62356","article-title":"The role of HE4 in differentiating benign and Malignant endometrial pathology","volume":"87","author":"Gasiorowska","year":"2016","journal-title":"Ginekologia polska"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143639","article-title":"Two dimensional-difference in gel electrophoresis (2D-DIGE) proteomic approach for the identification of biomarkers in endometrial cancer serum","volume":"13","author":"Ura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1540886","article-title":"The role of biomarkers in endometrial cancer and hyperplasia: a literature review","volume":"58","author":"Hutt","year":"2019","journal-title":"Acta Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594271","article-title":"Chimeric antigen receptor T-cell therapy in glioblastoma: current and future","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"95","DOI":"10.17772\/gp\/1602","article-title":"The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer","volume":"84","author":"Gottwald","year":"2013","journal-title":"Ginekologia polska"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1111\/j.8755-8920.2001.450603.x","article-title":"Mammalian expression cloning of two human trophoblast suppressors of major histocompatibility complex genes","volume":"45","author":"Peyman","year":"2001","journal-title":"Am J Reprod Immunol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152420","article-title":"Predictive biomarkers for immunotherapy in endometrial carcinoma","volume":"17","author":"Pizzimenti","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:29:35Z","timestamp":1760678975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":160,"alternative-id":["10.3389\/fimmu.2025.1684549"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1684549","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1684549"}}